LIGAND PHARMACEUTICALS INC (LGND)

194.23 -2.74 (-1.39%)

As of 2025-12-02 05:37:49 EST

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.

Traded asNasdaq: LGND
ISINUS53220K5048
CIK0000886163
LEI5493008K7TB0IKP37H79
EIN770160744
Sector—
IndustryPharmaceutical Preparations
CEOTodd C. Davis
Employees68
Fiscal Year End1231
Address3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA, 92121
Phone858-550-7500
Websitehttp://ligand.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
LGNDLIGAND PHARMACEUTICALS INC2025-12-02 05:37:49194.23-2.74-1.39
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
LGND0000886163LIGAND PHARMACEUTICALS INCUS53220K50485493008K7TB0IKP37H79770160744Nasdaq2834Pharmaceutical Preparations1231DE3911 SORRENTO VALLEY BLVDSAN DIEGOCA92121UNITED STATESUS858-550-75003911 SORRENTO VALLEY BLVD, SAN DIEGO, CA, 921213911 SORRENTO VALLEY BLVD, SAN DIEGO, CA, 92121LIGAND PHARMACEUTICALS—1987Todd C. Davis68http://ligand.com1,100,000,00019,656,00019,681,720Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.2025-11-27 16:05:36
This is a preview of the latest data. Subscribe to access the full data.
LGND Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
LGND Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20241,100,000,000200,000,00022.222219,255,3531,550,0668.7548
2023900,000,000-100,000,000-1017,705,287628,6293.6812
20221,000,000,000-800,000,000-44.444417,076,658224,0081.3292
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Andrew ReardonChief Legal Officer, Secretary2024451,950—1,428,806240,0007,3803,270,956
Matthew KorenbergChief Operating Officer, President2024385,545—6,716,643142,789118,32613,165,669
Todd C. DavisChief Executive Officer2024695,834—6,429,536637,0009,96012,914,980
Tavo EspinozaChief Financial Officer2024469,550—1,428,806250,0007,3803,298,556
Andrew ReardonChief Legal Officer, Secretary2023434,262—1,126,169173,7056,9002,337,081
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202468
202358
202276
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue167,133,000131,314,000196,245,000
Cost Of Revenue———
Gross Profit———
Research And Development Expenses21,425,00024,537,00036,082,000
General And Administrative Expenses78,654,00052,790,00070,062,000
Operating Expenses———
Operating Income-22,606,00011,942,0003,037,000
Net Income-4,032,00052,154,000-33,361,000
Earnings Per Share Basic-0.223.02-1.98
Earnings Per Share Diluted-0.222.94-1.98
Weighted Average Shares Outstanding Basic18,290,00017,298,00016,868,000
Weighted Average Shares Outstanding Diluted18,290,00017,757,00016,868,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents72,307,00022,954,00045,006,000
Marketable Securities Current183,858,000147,355,000166,864,000
Accounts Receivable38,376,00032,917,00030,424,000
Inventories14,114,00023,969,00013,294,000
Non Trade Receivables4,073,0006,395,0004,614,000
Other Assets Current16,897,0002,657,0003,399,000
Total Assets Current331,559,000237,429,000263,601,000
Marketable Securities Non Current———
Property Plant And Equipment15,133,00015,607,00012,482,000
Other Assets Non Current6,924,0005,923,0004,736,000
Total Assets Non Current610,215,000549,787,000499,067,000
Total Assets941,774,000787,216,000762,668,000
Accounts Payable5,233,0002,427,0005,307,000
Deferred Revenue1,278,0001,222,000355,000
Short Term Debt———
Other Liabilities Current27,906,00012,467,00015,681,000
Total Liabilities Current37,112,00016,782,00098,810,000
Long Term Debt——0
Other Liabilities Non Current30,163,00027,758,00021,966,000
Total Liabilities Non Current74,223,00069,521,00066,373,000
Total Liabilities111,335,00086,303,000165,183,000
Common Stock20,00018,00017,000
Retained Earnings498,984,000503,016,000450,862,000
Accumulated Other Comprehensive Income-5,942,000-817,000-984,000
Total Shareholders Equity830,439,000700,913,000597,485,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization35,239,00036,521,00051,534,000
Share Based Compensation Expense41,089,00025,743,00060,285,000
Other Non Cash Income Expense-20,010,000250,000—
Change In Accounts Receivable6,459,0002,601,000-55,319,000
Change In Inventories-9,619,00010,870,000-12,058,000
Change In Non Trade Receivables-2,310,0001,781,000-1,579,000
Change In Other Assets———
Change In Accounts Payable13,903,000-4,704,000-3,340,000
Change In Other Liabilities-1,291,0009,865,000-6,342,000
Cash From Operating Activities97,047,00049,577,000137,850,000
Purchases Of Marketable Securities226,384,000126,764,00051,226,000
Sales Of Marketable Securities229,367,000148,765,000209,561,000
Acquisition Of Property Plant And Equipment1,821,0003,521,00017,923,000
Acquisition Of Business010,405,0000
Other Investing Activities00960,000
Cash From Investing Activities-143,664,000-11,682,000163,624,000
Tax Withholding For Share Based Compensation5,136,0004,547,0008,236,000
Payments Of Dividends———
Issuance Of Common Stock37,140,000——
Repurchase Of Common Stock000
Issuance Of Long Term Debt———
Repayment Of Long Term Debt076,854,000260,949,000
Other Financing Activities65,200,00022,200,0002,600,000
Cash From Financing Activities97,141,000-59,947,000-275,990,000
Change In Cash49,353,000-22,052,00025,484,000
Cash At End Of Period72,307,00022,954,00045,006,000
Income Taxes Paid19,206,0008,770,00011,642,000
Interest Paid263,000288,0001,428,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share-0.223.02-1.98
Price To Earnings Ratio-487.045523.649-33.7374
Earnings Growth Rate-107.2848-252.5253-157.5581
Price Earnings To Growth Ratio4.5397-0.09370.2141
Book Value Per Share45.40440.519935.4212
Price To Book Ratio2.35991.76261.8859
Ebitda53,450,00098,101,00031,614,000
Enterprise Value——1,081,776,400
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio——0
Capital Expenditures34,765,00039,646,00043,505,000
Free Cash Flow62,282,0009,931,00094,345,000
Return On Equity-0.00490.0744-0.0558
One Year Beta1.34660.86331.2298
Three Year Beta1.17871.1331.1286
Five Year Beta1.12131.13431.1719
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
LAMATTINA JOHN LDirector2025-11-072,145A32,869
LAMATTINA JOHN LDirector2025-11-072,145D30,724
LAMATTINA JOHN LDirector2025-11-072,034A32,758
LAMATTINA JOHN LDirector2025-11-072,145D0
Gray Nancy RyanDirector2025-11-073,556A11,650
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Lamar Smith2018-01-09TX21Purchase2017-12-01—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
NOMURA HOLDINGS INC2025-09-3021,498,242121,363177.14
Fiduciary Trust Co2025-09-30300,7841,698177.1402
Binnacle Investments Inc2025-09-308865177.2
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC2025-09-3066,711,102376,601177.14
OSAIC HOLDINGS, INC.2025-09-3017,812,781100,742176.8158
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
RYDEX SERIES FUNDS2025-09-30Class CRYCMX274,782.780.0716
RYDEX SERIES FUNDS2025-09-30Class ARYAKX274,782.780.0716
RYDEX SERIES FUNDS2025-09-30Class HRYMKX274,782.780.0716
RYDEX SERIES FUNDS2025-09-30Class HRYRHX447,794.160.0629
RYDEX SERIES FUNDS2025-09-30Class CRYROX447,794.160.0629
This is a preview of the latest data. Subscribe to access the full data.